ICON issues 2025 guidance, stock slides 8%
ICON (NASDAQ:ICLR) stock fell 8% early Tuesday after it issued financial guidance for 2025. The clinical research ...
Icon (ICLR) Receives a Buy from RBC Capital
RBC Capital analyst Sean Dodge maintained a Buy rating on Icon (ICLR – Research Report) yesterday and set a price target of $263.00. The ...
ICON Backs Annual Guidance, Initiates 2025 Outlook; Pre-Market Stock Down
ICON Plc (ICLR), healthcare intelligence and clinical research company, on Tuesday reaffirmed its annual guidance. In addition, the ...
Morningstar5d
ICON Equity Institutional IOLZX
ICON Equity Fund earns an Average Process Pillar ... Analyzing additional factors, this strategy continually held some stocks with low trading volume over the last few years.
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts ...